


## Aganepag isopropyl

<b>Cat. No.:</b>	HY-19923	
<b>CAS No.:</b>	910562-20-8	
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>37</sub> NO <sub>4</sub> S	
<b>Molecular Weight:</b>	471.65	
<b>Target:</b>	Prostaglandin Receptor	
<b>Pathway:</b>	GPCR/G Protein	
<b>Storage:</b>	Pure form	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 200 mg/mL (424.04 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	2.1202 mL	10.6011 mL	21.2022 mL
<b>5 mM</b>	0.4240 mL	2.1202 mL	4.2404 mL
<b>10 mM</b>	0.2120 mL	1.0601 mL	2.1202 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Aganepag isopropyl (AGN-210961) is an EP2 agonist <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	EP
<b>In Vitro</b>	Aganepag isopropyl (AGN-210961) is an EP2 agonist <sup>[1][2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Impagnatiello F, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. *Br J Pharmacol.* 2019;176(8):1079-1089.
- [2]. Matsou A, et al. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma. *Expert Opin Investig Drugs.* 2018;27(10):777-785.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA